PHAR: חוב לטווח קצר של החברה Pharming Group N.V.

Pharming Group N.V. (PHAR) demonstrates absolute independence from economic cycles and external shocks. The quote characteristics for the separate_debt_short metric are at 0.01. The company relies on the rapid development of its rare disease therapy pipeline, expanding its market reach. High margins are driven by the easy replication of existing formulas, making the production model extremely efficient for global scaling.

Pharming Group N.V. specializes in developing drugs for the treatment of rare immune pathologies. An analysis of the current volume of short-term loans demonstrates the company's obligations with maturities of up to one year. This metric measures the efficiency of operational liquidity management and the management's ability to service debt using current cash flows. For the biopharmaceutical sector, this is a critical marker of financial stability when scaling gene therapy. The stability of this indicator confirms the fundamental reliability of the business.